ArticleOncotarget2017
Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy.Cancers · 2025Review
- Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model.Cancers · 2023Article
- Tackling Issues Observed during the Development of a Liquid Chromatography Method for Small Molecule Quantification in Antibody-Chelator Conjugate.Molecules (Basel, Switzerland) · 2023Article
- Glypican-3-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- HarnessingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Review
- Targeted thorium-227 conjugates as treatment options in oncology.Frontiers in medicine · 2022Review
- Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model.Frontiers in medicine · 2022Article
- Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.Molecules (Basel, Switzerland) · 2021Review
- Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications.Pharmaceutics · 2021Review
- Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".Pharmaceutics · 2021Review
- Article
- Alpha emitting nuclides for targeted therapy.Nuclear medicine and biology · 2021Review
- Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.Cancer biotherapy & radiopharmaceuticals · 2020Review
- Radium-223 mechanism of action: implications for use in treatment combinations.Nature reviews. Urology · 2019Review
- Development of Targeted Alpha Particle Therapy for Solid Tumors.Molecules (Basel, Switzerland) · 2019Review
- Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation.Cancer research · 2019Article
- Advances in targeted alpha therapy for prostate cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Review
- Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Synergistic Effect of a Mesothelin-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cell surface receptor CD70 has been previously reported as a promising target for B-cell lymphomas and several solid cancers including renal cell carcinoma. We describe herein the characterization and efficacy of a novel CD70 targeted thorium-227 conjugate (CD70-TTC) comprising the combination of the three components, a CD70 targeting antibody, a chelator moiety and the short-range, high-energy alpha-emitting radionuclide thorium-227 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.